Damora 制药
DMRA
18.44
-0.30
-1.60%
Damora 制药
US · DMRA
#3109 按市值排名
上市于 1970
18.44
-0.30
-1.60%
实时 - 追踪5344个代码 - 心跳于202秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 112.30% +0.02pp
- 机构数量
- 124
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund46.16%
Hedge Fund38.54%
VC/PE Fund19.41%
Private Company6.73%
Public Company1.26%
Individual/Insider1.07%
Government Pension Fund0.20%
主要股东 截至 2026-06-30
FMR
14.96% · 9.23M 股
Fairmount Funds Management LLC
14.11% · 8.71M 股
Avoro Capital Advisors LLC
6.13% · 3.78M 股
VR Management, LLC
5.84% · 3.60M 股
BlackRock
5.12% · 3.16M 股
Forbion Capital Partners B.V.
3.95% · 2.44M 股
RA Capital Management, L.P.
3.89% · 2.40M 股
Viking Global Investors LP
3.74% · 2.31M 股
Janus Henderson Group plc
3.70% · 2.28M 股
Panorama Holdings, LLC
3.31% · 2.05M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 34次买入 · 11次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Fairmount Funds Management LLC | -- | 14.11% |
| Jennifer Jarrett | Chief Executive Officer | 0.83% |
| Julianne Bruno | Independent Director | 0.22% |
| Hans Schambye | Chief Executive Officer | 0.01% |
| Garrett Winslow | Senior Vice President | 0.00% |
| Lori Firmani | Interim Chief Financial Officer | 0.00% |
| Jonathan Freve | Chief Financial Officer | 0.00% |
| Carl Goldfischer | Independent Chairperson | 0.00% |
| David Shapiro | Independent Director & Member of the Clinical Advisory Board - Liver cirrhosis | -- |
| Amy Wechsler | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-24 | Jennifer Jarrett | Chief Executive Officer | Open Market Acquisition | +12,500 | $20.23 |
| 2026-08-11 | Andrew Cheng | Director | Other Derivative Acquisition | +30,350 | $31.00 |
| 2026-08-04 | Lori Firmani | Interim Chief Financial Officer | Intent to Sell (Form 144) | -1,800 | $31.10 |
| 2026-07-05 | Garrett Winslow | Senior Vice President | Derivative Exercise and Sale | -245 | $29.98 |
| 2026-07-02 | Garrett Winslow | Senior Vice President | Derivative Exercise and Retained | +435 | -- |
| 2026-06-21 | Lori Firmani | Interim Chief Financial Officer | Intent to Sell (Form 144) | -7,615 | $25.36 |
| 2026-04-30 | Brian Burkavage | Senior VP of Finance, Principal Financial & Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-29 | Jennifer Jarrett | Chief Executive Officer | Other Acquisition | +500,000 | -- |
| 2026-03-29 | Jennifer Jarrett | Chief Executive Officer | Other Derivative Acquisition | +1,500,000 | $25.50 |
| 2026-03-22 | Michael Landsittel | Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Christopher Cain | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Garrett Winslow | Senior Vice President | Other Derivative Acquisition | +250,000 | $23.05 |
| 2026-03-22 | Cameron Turtle | Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Peter Harwin | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Julianne Bruno | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-02-08 | Fairmount Funds Management LLC | -- | Derivative Exercise and Retained | +8,713,000 | -- |
| 2026-02-08 | Julianne Bruno | Independent Director | Derivative Exercise and Retained | +129,000 | -- |
| 2026-01-04 | Becker Hewes | Chief Medical Officer | Other Acquisition | +264,629 | -- |
| 2026-01-04 | Becker Hewes | Chief Medical Officer | Other Derivative Acquisition | +528,603 | $21.82 |
| 2026-01-04 | Sherwin Sattarzadeh | Chief Operating Officer | Other Acquisition | +190,376 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Damora 制药 讨论区 0 条评论